Ralph H. Thurman
Lead Independent DirectorMr. Ralph H. Thurman, also known as Randy, served as an Operating Advisor and previously served as a Senior Advisor at BC Partners LLP since joining the firm in 2015 and as the Executive Chairman of the Board of Directors of Zest Dental, Inc. He serves as Director at uMETHOD Health Inc since 2024. He had been Executive Chairman at Outlook Therapeutics, Inc. since June 18, 2018, until January 31, 2025 and also serves as Lead Independent Director Since January 31, 2025 and has been its Director since April 2018. He had been Executive Chairman of the Board at Presbia PLC since January 2015. He had been a Director of TFF Pharmaceuticals, Inc. since April 2019 until September 30, 2022. Mr. Thurman served as Chief Executive Officer at Presbia PLC since October 2014 until January 2015. He currently serves as a senior advisor to GMS Capital Partners, Vice Chairman of Syntone Biotech and an Adjunct Professor — Finance at Merrimack College Graduate School. He has been a Director at Presbia Coöperatief U.A. since October 2013 and Presbia PLC since February 2014. He has served as a consulting advisor in private equity since 2008. He served as the Chief Executive Officer at BioTelemetry, Inc., from January 2009 to June 2010 and its Interim Chief Executive Officer from January 2009 to February 25, 2009; President from January 2009 to June 2010; Interim President from January 2009 to February 25, 2009; Executive Chairman from July 9, 2008, to October 26, 2011 also Chairman from June 2009 to October 2011. He served as an Operating Executive and Partner at AEA Investments LP (“AEA Investments”), from October 2012 to March 2014. He served as an Operating Executive at AEA Investors LP. He served as Senior Advisor and Operating Partner at New Mountain Partners III, L.P., New Mountain Partners, L.P., Allegheny New Mountain Partners, L.P. and New Mountain Partners II, L.P. Mr. Thurman served as a Senior Advisor at New Mountain Capital, LLC since May 2008 and its Operating Partner since April 2008. He served as President, Chief Executive Officer and Director at Aventis Pharmaceuticals Inc. He served as the Chief Executive Officer of Cogent Healthcare, Inc. from July 17, 2013, to July 22, 2013 and also its Executive Chairman. From July 2007 to June 2008, he served as a Consultant at Cardinal Health, Inc. He served as a Consultant at from July 2007 to June 2008. He held various positions at Rhone-Poulenc Rorer Pharmaceuticals, Inc. from 1984 to 1993. He served as the Chairman and Chief Executive Officer at Corning Life Sciences B.V., from 1993 to 1997. He was a Consultant and Chairman of Orthofix International N.V from November 6, 2013, to January 2014. From 2000 to 2007, he was a Founder, Chairman and Chief Executive Officer of VIASYS Healthcare Inc. He served as Chief Executive Officer of CareFusion 202, Inc., since April 2001 and its President since July 26, 2004. From 2008 to 2011, Mr. Thurman served as Executive Chairman of CardioNet Inc. (now known as BioTelemetry, Inc.) and as its interim Chief Executive Officer from 2008 until 2010. He was employed at Pepsico, Inc. From 1997 to 2001, Mr. Thurman served as Chairman and Chief Executive Officer of Strategic Reserves LLC. From July 2008 to October 2011, he served as a Director of BioTelemetry, Inc., where he also served as Executive Chairman from July 2008 to 2011, as President and Chief Executive Officer from February 2009 to June 2010 and as Chairman from June 2009 until his resignation from the Board of Directors in October 2011. He served as an Executive Chairman and Executive Director at CareFusion 202, Inc., since May 2002. He served as the Chief Executive Officer of Presbia PLC from October 2014 to January 2015. He served as Executive Chairman of Presbia PLC (an Orchard Capital Corporation company), a publicly-traded medical device company. He served as a Vice Chairman and Director of Arno Therapeutics, Inc. from March 24, 2014, to December 4, 2014. He served as a Director of Enzon Pharmaceuticals, Inc. and CuraGen Corporation. He has been Director of Outlook Therapeutics, Inc. since April 13, 2018. He served as a Director of Closure Medical Corporation, Inc., since May 1996; Metpath, Inc.; Ikaria, Inc., since November 2007; Flamel Technologies SA since June 22, 2005, until January 10, 2006 and Valeant Pharmaceuticals International from 2002 to April 4, 2006. He served as a Director at Allscripts Healthcare Solutions, Inc., since June 2012 until May 2018. He served as a Director of Orthofix International N.V since November 6, 2013, until to February 2014. He served as a Director of Enzon, Inc., from 1993 to 2001 and served as Chairman from 1996 to 2001. He is a Member of the Board of Trustee at Malvern Preparatory School. He is a Member of the Executive Investment Council at Leavitt Equity Partners. He is an Adjunct Professor — Finance at Merrimack College Graduate School. In 2007, Mr. Thurman was named an Entrepreneur of the Year by Ernst & Young. Mr. Thurman served as a fighter pilot in the United States Air Force and Air National Guard from 1971 to 1992. Mr. Thurman received his B.S. degree in Economics from Virginia Polytechnic Institute, earned an M.A. in management from Webster University and is a graduate of the USAF Air Command and Staff Leadership College.
Positions
- Company NameOutlook Therapeutics, Inc.Stock CodeOTLKPositionLead Independent DirectorColleagues
- RCRobert Charles JahrPresident, CEO & Director
- FGFaisal G. SukhtianIndependent Chairman of the Board
- KLKevin LundquistCFO, Treasurer, Principal Financial Officer & Principal Accounting Officer
- JPJoel PrieveSenior Vice President of Licensing and M&A
- SSSurendra SharmaSenior Vice President of Medical Affairs
- JMJennifer M. KissnerSenior Vice President of Clinical Development & Regulatory Affairs
- KJKurt J. HilzingerIndependent Director
- YMYezan M. HaddadinIndependent Director
